Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

Share Price is delayed by 15 minutes
Get Live Data
41.50    0.00 (0.00%)
Bid:
41.50
Ask:
42.70
Spread: 1.20 (2.892%)
Market Cap: £30.06m
NCYT Live PriceLast checked at - London Stock Exchange

Intraday Novacyt Share Chart

PLACED IN TECHNOLOGY FAST 500 EMEA AWARDS

2 Jan 2018 07:00

RNS Number : 6349A
Novacyt S.A.
02 January 2018
 

FOR THE THIRD YEAR RUNNING NOVACYT IS PLACED IN THE TECHNOLOGY FAST 500 EMEA AWARDS

 

Paris, France and Cambridge, UK - 2 January 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte's Technology Fast 500™ EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth in Europe, the Middle East and Africa (EMEA).

 

Novacyt has delivered strong revenue growth averaging 113% between 2013 and 2016. In 2016, the Group generated revenues of €11.1 million on a consolidated basis, representing annual growth of 25%, with a 55% gross profit margin, which was an increase of seven percentage points on the previous year.

 

Graham Mullis, Group CEO of Novacyt, commented:

"We are delighted to once again be placed in the Technology Fast 500 EMEA awards. This year Novacyt has received its highest ever ranking. The commitment to our three core strategic pillars is enabling us to deliver strong growth and puts us on a pathway to sustainable profitability.

 

"I would like to thank all our employees for their dedication and commitment in driving our business forward culminating in this achievement and I look forward to updating shareholders of our full year 2017 sales later this month."

 

- End -

 

 

About Deloitte Global's 2017 Technology Fast 500 EMEA program

 

Deloitte Global's Technology Fast 500™ EMEA program is an objective industry ranking focused on the technology ecosystem. It recognizes technology companies that have achieved the fastest rates of revenue growth in Europe, the Middle East, and Africa (EMEA) during the past four years. The program is supported by Deloitte Global's Technology Fast 50 initiatives, which rank high-growth technology companies by location or specifically defined geographic area, and are run by Deloitte Global's Technology, Media & Telecommunications (TMT) industry group. More information on the program is available at www.deloitte.com/fast500emea 

 

Now in its seventeenth year, the Technology Fast 500 program in EMEA included over 18 countries, including Belgium, France, Finland, Germany, Italy, the Netherlands, Turkey and the UK. This year's winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016.

 

Sponsors of Deloitte Global's 2017 Technology Fast 500 EMEA program are Euronext, a pan-European exchange that helps tech companies finance growth and innovative projects through the stock market; Oracle NetSuite, provider of cloud-based financials / Enterprise Resource Planning (ERP), HR and omnichannel commerce software that runs the business of companies in more than 100 countries; and Michael Page, recognized by clients and candidates the world over as the leading specialist consultancy in permanent recruitment, temporary staffing and interim management.

 

 

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

 

For more information please refer to the website: www.novacyt.com 

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1223 395472

 

Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)

Jonathan Senior / Fred Walsh / Ben Maddison

+44 (0)20 7610 7600

 

International

Brett Pollard / Victoria Foster Mitchell

FTI Consulting

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com 

 

France

Arnaud de Cheffontaines / Astrid Villette

FTI Consulting

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASSDFMFFASESF
Date   Source Headline
1st Jun 20262:45 pmRNSLiquidity Agreement Monthly Update and TVR
1st Jun 20269:45 amRNSOperational Update
22nd May 20267:00 amRNSNotice of AGM
19th May 20267:00 amRNSLaunch of Yourgene® Insight DPYD assay
7th May 202610:00 amRNSDirectorate change
5th May 20262:00 pmRNSLiquidity Agreement Monthly Update and TVR
30th Apr 20267:00 amRNSFull Year 2025 results
8th Apr 20267:00 amRNSNotice of Results and Investor Presentation
1st Apr 202611:45 amRNSLiquidity Agreement Monthly Update and TVR
30th Mar 20263:00 pmRNSDirector/PDMR Shareholding
20th Mar 20267:00 amRNSResult of Preferential Subscription Rights Issue
2nd Mar 20263:30 pmRNSLiquidity Agreement Monthly Update and TVR
2nd Mar 20267:02 amRNSPreferential Subscription Rights Issue
2nd Mar 20267:00 amRNSCompletion of Acquisition
23rd Feb 20267:00 amRNSAcquisition of Southern Cross Diagnostics
2nd Feb 20263:45 pmRNSLiquidity Agreement Monthly Update and TVR
27th Jan 20267:00 amRNSNIPT Tender Award
21st Jan 20267:00 amRNSFull year trading update
2nd Jan 20261:30 pmRNSLiquidity Agreement Monthly Update and TVR
1st Dec 202512:00 pmRNSLiquidity Agreement Monthly Update and TVR
3rd Nov 20252:30 pmRNSLiquidity Agreement Monthly Update and TVR
22nd Oct 20257:00 amRNSStrategy update & notice of investor presentation
1st Oct 20254:00 pmRNSLiquidity Agreement Monthly Update and TVR
30th Sep 20257:00 amRNS2025 Interim results
18th Sep 20257:00 amRNSNotice of Results
15th Sep 20257:00 amRNSAppointment of Joint Corporate Broker
12th Sep 202510:00 amRNSResolution re. Lab 21 HSE Prosecution
1st Sep 20251:45 pmRNSLiquidity Agreement Monthly Update and TVR
1st Aug 20254:02 pmRNSLiquidity Agreement Monthly Update & TVR
29th Jul 20257:00 amRNSHalf-year trading update
15th Jul 20257:00 amRNSLaunch of LightBench® Discover
1st Jul 20251:45 pmRNSLiquidity Agreement Monthly Update and TVR
20th Jun 20257:00 amRNSResult of AGM
16th Jun 20257:00 amRNSPublication of Annual Report
2nd Jun 202511:30 amRNSLiquidity Agreement and Total Voting Rights
28th May 20257:00 amRNSAGM Voting
12th May 20257:00 amRNSNotice of AGM
2nd May 202512:30 pmRNSLiquidity Agreement Monthly Update and TVR
30th Apr 20257:00 amRNSFull Year 2024 Results
22nd Apr 20257:00 amRNSNotice of Results
1st Apr 202511:45 amRNSLiquidity Agreement and Total Voting Rights
18th Mar 20254:15 pmRNSUpdate re. Lab 21 HSE Prosecution
3rd Mar 20253:00 pmRNSLiquidity Agreement and Total Voting Rights
20th Feb 20257:00 amRNSIVDR accreditation for Yourgene QST*R Base assay
3rd Feb 20252:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20257:00 amRNSFull year trading update
21st Jan 20253:30 pmRNSStatement re. HSE Prosecution
2nd Jan 20253:15 pmRNSLiquidity Agreement Monthly Update and TVR
10th Dec 20247:00 amRNSChange of Registered Office
2nd Dec 20244:00 pmRNSLiquidity Agreement and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.